In our 2018 U.S. Transparency Report, we reported a 6.8% decrease in the average net price of its medicines, marking the second consecutive year of net price reductions. We invested $8.4 billion in global research and development—86% more than our spending on marketing and sales—and assisted approximately 1 million patients with access, affordability and treatment support through the Janssen CarePath program.
Read the executive summary below, or view the full report here.
All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.